




RealRate

PHARMACEUTICAL 2018

NovaBay Pharmaceuticals Inc.
Rank 236 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 574% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 580% points.

The company's Economic Capital Ratio, given in the ranking table, is -310%, being 32% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	8,995
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,979
Liabilities, Non-Current	215
Other Assets	613
Other Compr. Net Income	0
Other Expenses	16,599
Other Liabilities	2,291
Other Net Income	12
Property and Equipment	471
Research and Development	410
Revenues	18,230
Selling, General and Administrative Expense	8,636

Output Variable	Value in 1000 USD
Assets	10,079
Liabilities	7,485
Expenses	25,645
Stockholders Equity	2,594
Net Income	-7,403
Comprehensive Net Income	-7,403
Economic Capital Ratio	-310%